Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research Focus on Women’s Mental Health October 22, 2025

Balancing Mental Health and Breastfeeding: Evaluating the Transfer of Lurasidone Into Human Milk

; ;

J Clin Psychiatry. 2025;86(4):25m15955

Abstract

Objective: Lurasidone, a second-generation atypical antipsychotic, lacks significant published data on its transfer into human milk during lactation. The objective of this study was to (1) quantify the transfer of lurasidone into human milk, allowing for an estimation of maternal drug exposure to the breastfed infant and (2) report observations of infants exposed to lurasidone via breast milk.

Methods: Milk samples and health histories were collected from 9 lactating mothers who donated milk samples to the InfantRisk Human Milk Biorepository while taking lurasidone (20–80 mg/day) from 2022 to 2024. The drug concentration-time profile of lurasidone in milk was determined using liquid chromatography–mass spectrometry, and maternal lurasidone doses were standardized to 40 mg/day.

Results: Lurasidone had an average milk concentration of 39.5 ng/mL at the 40 mg/day standardized dose. The relative infant dose (RID) was 1.16%, which is below the standard 10% threshold for infant safety. Even using the highest observed individual concentration of 174 ng/mL, the calculated RID was 3.03%. There were no maternal reports of adverse effects in the infants exposed to varying degrees of lurasidone in milk.

Conclusion: The levels of lurasidone observed in all participants’ milk samples were exceedingly low. The subsequently low RID is below the 10% threshold for infant safety, suggesting that the transfer of maternal lurasidone into human milk is clinically insignificant and poses minimal risk to a breastfed infant.

J Clin Psychiatry 2025;86(4):25m15955

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251. PubMed CrossRef
  2. Masters GA, Hugunin J, Xu L, et al. Prevalence of bipolar disorder in perinatal women: a systematic review and meta-analysis. J Clin Psychiatry. 2022;83(5):21r14045. PubMed CrossRef
  3. Davanzo R, Bua J, De Cunto A, et al. Advising mothers on the use of medications during breastfeeding: a need for a positive attitude. J Hum Lact. 2016;32(1):15–19. PubMed CrossRef
  4. Jayawickrama HS, Amir LH, Pirotta MV. GPs’ decision-making when prescribing medicines for breastfeeding women: content analysis of a survey. BMC Res Notes. 2010;3:82. PubMed CrossRef
  5. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013;16(2):149–157. PubMed CrossRef
  6. Petersen I, McCrea RL, Osborn DJ, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res. 2014;159(1):218–225. PubMed CrossRef
  7. Viguera AC, Vanderkruik R, Gaccione P, et al. Breastfeeding practices among women taking second-generation antipsychotics: findings from the National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health. 2022;25(2):511–516. PubMed CrossRef
  8. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–1923. PubMed CrossRef
  9. Solé E, Torres A, Roca A, et al. Obstetric complications in bipolar disorder: the role of mental health disorders in the risk of caesarean section. J Affect Disord. 2019;252:458–463. PubMed
  10. Miller ES, Metz T, Moore-Simas TA, et al. Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141(6):1262–1288. PubMed
  11. Latuda (lurasidone). Package insert. Sunovion Pharmaceuticals Inc.; 2018.
  12. Feng Y, Shi J, Wang L, et al. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry Clin Neurosci. 2020;74(6):336–343. PubMed CrossRef
  13. Agapoff JR, Olson DJ, White S, et al. Rapid and sustained resolution of risperidone associated hyperprolactinemia and galactorrhea with low-dose lurasidone. J Clin Psychopharmacol. 2020;40(4):410–412. PubMed CrossRef
  14. Keightley P, Schmidt Sotomayor N, O’Hara K, et al. Lurasidone in lactation: a case study with laboratory and clinical outcomes. Aust N Z J Psychiatry. 2020;54(10):1035–1036. PubMed CrossRef
  15. Montiel C, Newmark RL, Clark CT. Perinatal use of lurasidone for the treatment of bipolar disorder. Exp Clin Psychopharmacol. 2022;30(2):249–252. PubMed CrossRef
  16. Clinical lactation studies: considerations for study design. U.S. Food and Drug Administration; 2020. Accessed May 6, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design. PubMed CrossRef
  17. Anderson PO. Antidepressants and breastfeeding. Breastfeed Med. 2021;16(1):5–7. PubMed CrossRef
  18. Cohen LS, Church TR, Freeman MP, et al. Reproductive safety of lurasidone and quetiapine: update from the National Pregnancy Registry for Psychiatric Medications. J Womens Health (Larchmt). 2023;32(4):452–462. PubMed CrossRef
  19. Pathirana MM, Andraweera PH, Aldridge E, et al. The association of breast feeding for at least six months with hemodynamic and metabolic health of women and their children aged three years: an observational cohort study. Int Breastfeed J. 2023;18(1):35. PubMed CrossRef
  20. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. PubMed CrossRef
  21. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry. 2008;69(4):666–673. PubMed CrossRef
  22. Hale TW, Krutsch K. Hale’s Medications & Mothers’ Milk 2025–2026: A Manual of Lactational Pharmacology. 21st ed. Springer Publishing Company; 2024.
  23. Caplyta (lumateperone). Package insert. Intra-Cellular Therapies Inc.; 2023.
  24. Seroquel (quetiapine). Package insert. AstraZeneca Pharmaceuticals. LP; 2013.
  25. Croke S, Buist A, Hackett LP, et al. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol. 2002;5(3):243–247. PubMed CrossRef
  26. Gardiner SJ, Kristensen JH, Begg EJ, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry. 2003;160(8):1428–1431. PubMed CrossRef
  27. Lutz UC, Wiatr G, Orlikowsky T, et al. Olanzapine treatment during breast feeding: a case report. Ther Drug Monit. 2008;30(3):399–401. PubMed CrossRef
  28. Aydin B, Nayir T, Sahin S, et al. Olanzapine and quetiapine use during breastfeeding: excretion into breast milk and safe breastfeeding strategy. J Clin Psychopharmacol. 2015;35(2):206–208. PubMed CrossRef
  29. Manouilenko I, Öhman I, Georgieva J. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. Arch Womens Ment Health. 2018;21(5):587–589. PubMed CrossRef
  30. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066–1078. PubMed CrossRef
  31. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73(4):330–337. PubMed CrossRef
  32. Symbyax (olanzapine and fluoxetine). Eli Lilly and Company; 2009.
  33. Moretti ME, Koren G, Verjee Z, et al. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther Drug Monit. 2003;25(3):364–366. PubMed CrossRef
  34. Bartick MC, Schwarz EB, Green BD, et al Suboptimal breastfeeding in the United States: maternal and pediatric health outcomes and costs [published correction appears in Matern Child Nutr. 2017;13(2):null]. Matern Child Nutr. 2017;13(1):e12366. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders

Original Research

Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders

Original Research

Niacin-Induced Response in Early Psychosis

Original Research

Early Ketamine Response Reduces Suicidal Events at 3 Months

Letter to the Editor

Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use

Original Research

Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia
View current Issue

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure shows a syringe and vials with title on aripiprazole monohydrate LAI use in schizophrenia and a red READ NOW button.

Subscribe to read
more articles

Subscribe